Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients

11:00 am - Wednesday 14th October 2026

Laying out CAN016 preclinical profile including monkey tox data supporting dual payload ADC IND approval
Contextualizing pre-IND filing approach as an emerging ADC modality, and strategy for HER2 refractory patient treatment
Highlighting ongoing first in-human development of CAN016 and potential impact in HER2 refractory patients resistant to Enhertu

Speakers:

Henry Yu

Henry Yu

Chief Executive Officer

CanWell Pharma Inc